August 2, 2019 / 8:44 AM / 4 months ago

BRIEF-Cyxone: Study Confirms Drug Candidate T20K's Safety And Tolerability In Humans

Aug 2 (Reuters) - Cyxone AB:

* SAID ON THURSDAY CLINICAL PHASE I TRIAL WITH DRUG CANDIDATE T20K SUCCESSFULLY ACHIEVED ITS PURPOSE OF CONFIRMING T20K’S SAFETY AND TOLERABILITY IN HUMANS

* THERE WERE NO REPORTS OF SERIOUS ADVERSE EVENTS IN THIS INFUSION STUDY

* T20K, WHICH IS UNDER DEVELOPMENT FOR THE TREATMENT OF MULTIPLE SCLEROSIS, WILL AS A NEXT STEP IN THE DEVELOPMENT PROGRAM BE PREPARED AS AN ORAL FORMULATION FOLLOWED BY A FURTHER CLINICAL PHASE I STUDY

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below